Where does Neurolens, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Neurolens, Inc. ranks #17,935 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Neurolens, Inc. hold?

Neurolens, Inc. holds 16 US utility patents granted between 2020 and 2025, spanning 9 technology areas.

What is Neurolens, Inc.'s Innovation Score?

Neurolens, Inc. has an Innovation Score of 43.8 out of 100 (top 27% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Neurolens, Inc. focus on?

Neurolens, Inc.'s top technology area is A61B (DIAGNOSIS; SURGERY; Identification) with 12 patents, ranking #1,451 of 7,127 assignees active in that subclass. Grants appear in 9 CPC subclasses total.

Is Neurolens, Inc.'s patent grant rate increasing or decreasing?

Insufficient historical data is available to calculate a velocity trend for Neurolens, Inc..

What does claim depth mean for Neurolens, Inc.'s patents?

Neurolens, Inc.'s patents average 16.8 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Neurolens, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Neurolens, Inc.

USPTO PatentsView assignee record - 16 granted patents across 9 technology areas, recorded in grant years 2020–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61B (DIAGNOSIS; SURGERY; Identification).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Neurolens ranks #17,935 of 49,997 tracked US assignees by granted-patent volume, with 16 patents across 9 technology areas.

#17,935
of 49,997 US assignees by volume: Top 27%
by Innovation Score (43.8/100): 16.8
avg claims per patent

USPTO PatentsView assignee plate

Corpus R17935 · US Corporation #17,935 · 16 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-RICH · TYPE-USCORP · SPAN-YRS · BOOK-RICH

GRANTS-MICRO 16 grants
MID-PACK #17,935/49,997
PHOTO-FINISH Nanjing Legend Biotech
CPC-NARROW A61B · 9 areas
INNOV-PAR 43.8/100
CLAIMS-RICH 16.8 claims/avg
TYPE-USCORP US Corporation
SPAN-YRS 2020–2025 · 6y
BOOK-RICH 9/10 fields

Nearest grant-volume peer: Nanjing Legend Biotech Co., Ltd (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Neurolens’s 43.8 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 9.8 pts (22%) Velocity 13.3 pts (30%) Breadth 10.6 pts (24%) Claim depth 10.1 pts (23%)

Qualcomm Incorporated · highest

85
Neurolens · this assignee

44
3D Lighting… · lowest

7

What this shows Neurolens's Innovation Score is 43.8/100 (top 27% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Neurolens?

Each dot is one of Neurolens’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Neurolens’s own 16.8 claims/patent is at or below the 17.4 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Neurolens vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Neurolens's grants concentrate

Neurolens, Inc. is a focused PatentsView assignee: 9 CPC subclasses with 75% of grants classified under A61B (DIAGNOSIS; SURGERY; Identification). Peak complete grant year is 2022 (5 grants) versus a trough of 1 in 2020. By volume, Neurolens sits between Nanjing Legend Biotech Co., Ltd and Nexark, Inc..

Neurolens's three-year grant acceleration

Neurolens, Inc. shows 10 grants in 2022–2024 against only 5 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Nanjing Legend Bi…

16
Nanotech Energy

16
Nectar

16
Neozyme Internati…

16
New Mexico Tech U…

16
Newave Pharmaceut…

16
Newco Enterprises

16
Nexark

16
Neurolens ◀

16

What this shows Neurolens holds 16 patents at rank #17,947, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Neurolens

By rank, the assignees closest to #17,947 in granted patent volume.

Leaders in A61B (Diagnosis)

Other assignees with the most granted patents in Neurolens's primary technology class.

Neurolens's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

44 Top 27% higher than 73% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2020–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2020–2019 baseline. Full figures in the table below.

View data table

Neurolens, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2020	1	6.3%
2021	4	25.0%
2022	5	31.3%
2023	2	12.5%
2024	3	18.8%
2025partial year	1	6.3%

Which technologies does Neurolens, Inc. patent most?

A61B - DIAGNOSIS; SURGERY; Identification 12

G02C - SPECTACLES; Sunglasses OR Goggles Insofar AS They Have THE Same Features AS SPECTACLES; Contact Lenses 10

G06F - Electric Digital Data Processing 8

G06N - Computing Arrangements Based ON Specific Computational Models 8

G02B - Optical Elements, Systems OR Apparatus 5

H04N - Pictorial Communication, e.g. Television 2

G06T - Image Data Processing OR Generation, IN General 1

G16H - Healthcare Informatics, i.e. Information AND Communication Technology [ICT] Specially Adapted FOR THE Handling OR Processing OF Medical OR Healthcare Data 1

B29D - Producing Particular Articles From Plastics OR From Substances IN A Plastic State 1

Top 9 of 9 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Neurolens, Inc.'s patent record in context - here's where to go next.

Neurolens, Inc.'s lead technology class is A61B (DIAGNOSIS; SURGERY; Identification), 75% of its portfolio - see every assignee active in that class. Explore A61B
Ranked #17,935 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Neurolens, Inc. against Nanjing Legend Biotech Co., Ltd, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 43.8/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.